Swollen Joint News and Research

RSS

Study investigates vitamin C's effectiveness in treating gout and hyperuricemia

Scientists at the University of Minnesota, USA, have initiated a study entitled “the Hmong Microbiome and Gout, Obesity, Vitamin C (HMANGO-C) study” to determine the effect of vitamin C supplementation on serum urate levels in Hmong adults with or without gout. Hmong (pronounced mung) is a racial group originally from the Southwest of China.

3 Apr 2023

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Data presented yesterday by researchers for Mallinckrodt plc, a leading specialty biopharmaceutical company, suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy.

10 Nov 2015

Hispanic mortality paradox found in RA patients

The so-called “Hispanic survival paradox” has been found to extend to patients with rheumatoid arthritis, whereby Hispanic people with the condition tend have more severe symptoms but equivalent mortality to non-Hispanic White individuals.

19 Dec 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

13 Jun 2013

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

New PSUMMIT 2 data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis.

13 Jun 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Researchers discover new gene for susceptibility to Alzheimer's disease

A large-scale international study involving French researchers from the Inserm-Institut Pasteur Lille-Universit- Lille Nord de France "Public health and molecular epidemiology of ageing-related diseases" joint research unit led by Philippe Amouyel, has just discovered a gene for susceptibility to a rare disease that causes susceptibility to a common one, Alzheimer's disease, providing evidence of the heterogeneous aetiology of Alzheimer's disease.

20 Nov 2012

Study quantifies discrepancies between physicians and patients with rheumatoid arthritis

For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.

23 Aug 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

Discrepancies between patients and physicians' views of RA disease activity

Researchers from Austria have determined that patients with rheumatoid arthritis (RA) and their doctors differ on perception of RA disease activity.

18 Jul 2012

Rheumatoid arthritis patients and their doctors differ on perception of disease activity

Researchers from Austria have determined that patients with rheumatoid arthritis (RA) and their doctors differ on perception of RA disease activity. The study now available in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR) and published by Wiley, reports that RA patients cite joint pain as the reason for their perception of a change in their disease activity. Rheumatologists, however, stressed joint swelling as the major determinant for their perception of change in RA disease activity.

18 Jul 2012

Simple blood test may help physicians track progression of RA disease activity

A simple blood test may help physicians track the progression of rheumatoid arthritis disease activity, say researchers at the University of Alabama at Birmingham.

27 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

SC formulation of Genentech’s ACTEMRA shows promise against RA

Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.

3 May 2012

New ACR classification criteria for polymyalgia rheumatica

The American College of Rheumatology has released the first classification criteria for polymyalgia rheumatica - aimed at helping physicians identify patients with this condition, which occurs in persons aged 50 years or older who have recent onset of pain in the shoulders, neck and hips along with other inflammatory symptoms not explained by an alternate diagnosis.

2 Mar 2012

Swollen Joint News and Research

Study investigates vitamin C's effectiveness in treating gout and hyperuricemia

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Hispanic mortality paradox found in RA patients

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Researchers discover new gene for susceptibility to Alzheimer's disease

Study quantifies discrepancies between physicians and patients with rheumatoid arthritis

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Discrepancies between patients and physicians' views of RA disease activity

Rheumatoid arthritis patients and their doctors differ on perception of disease activity

Simple blood test may help physicians track progression of RA disease activity

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

SC formulation of Genentech’s ACTEMRA shows promise against RA

New ACR classification criteria for polymyalgia rheumatica

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News